Brief: Bayer Submits Application For Next Indication Of Kerendia In China
30/07/2026 07:30
BRIEF-Bayer Submits Application For Next Indication Of Kerendia In China July 30 (Reuters) - Bayer AG BAYGn.DE:
REGULATORY SUBMISSION OF NEW INDICATION FOR PATIENTS WITH NON-DIABETIC CHRONIC KIDNEY DISEASE BASED ON POSITIVE DATA FROM PHASE III FIND-CKD STUDY
SUBMITS APPLICATION FOR NEXT INDICATION OF KERENDIA IN CHINA
Source text: [ID:]
Further company coverage: [BAYGn.DE]
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Bayer AG
See all newsBrief: Bayer Says Finerenone Slowed Kidney Decline In CKD
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Deutsche Bank AG FF - Post Stabilisation Notice -Bayer EUR 30NC6 & 30NC9
Brief: Bayer To Present New Finerenone Data Across Chronic Kidney Disease With And Without Diabetes At Asn Kidney Week 2026
Brief: FDA Approves Once-Weekly Generic Hormone Therapy Patch For Women